UPB

UpStream Bio Inc.

• TipRanks·2h ago

  Validating the IL-13/TSLP Axis: Upstream Bio’s Verekitug Positioned for Differentiated Asthma Efficacy and Favorable Risk–Reward

• Benzinga·8h ago

  From Lungs To Nasal Polyps: Sanofi Finds Success With 2-in-1 Inflammation Blocker

• Reuters·1d ago

  Upstream Bio publishes corporate presentation outlining verekitug Phase 3 plans in asthma, CRSwNP

• TipRanks·1d ago

  Analysts Offer Insights on Healthcare Companies: Upstream Bio, Inc. (UPB) and Pfizer (PFE)

• TipRanks·5d ago

  Piper Sandler Remains a Buy on Upstream Bio, Inc. (UPB)

• TipRanks·03/27 16:33

  VALIANT Asthma Trial Update: What Upstream Bio’s Phase 2 Milestone Means for Investors

• TipRanks·03/27 15:56

  Midday Fly By: Carnival cuts forecast on fuel cost, Novartis to buy Excellergy

• Dow Jones·03/27 14:57

  Upstream Bio Price Target Cut to $15.00/Share From $40.00 by Evercore ISI Group

• Dow Jones·03/27 14:57

  Upstream Bio Cut to In-Line From Outperform by Evercore ISI Group

• Benzinga·03/27 14:47

  Evercore ISI Group Downgrades Upstream Bio to In-Line, Lowers Price Target to $15

• TipRanks·03/27 13:51

  Wix downgraded, TripAdvisor upgraded: Wall Street’s top analyst calls

• Benzinga·03/27 12:10

  Zenas Biopharma, Daqo New Energy And Other Big Stocks Moving Lower In Friday's Pre-Market Session

• TipRanks·03/27 10:45

  Upstream Bio downgraded to In Line from Outperform at Evercore ISI

• TipRanks·03/26 21:30

  Upstream Bio Launches $150 Million At-The-Market Program

• Reuters·03/26 21:10

  Upstream Bio announces $150 million at-the-market equity distribution agreement with Leerink Partners